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These guidelines for Legally Defensible Workplace DrugTesting have been prepared and updated
by the European Workplace Drug Testing Society (EWDTS). The European Guidelines are
designed to establish best practice procedures whilst allowing individual countries to operate
within the requirements of national customs and legislation. The EWDTS recommends that all
European laboratories that undertake legally defensible workplace drug testing should use these
guidelines as a template for accreditation. These guidelines are relevant to laboratory‐based test-
ing only. These guidelines follow current best practices and are constantly under review.Q5
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1 | GENERAL
1.1 | IntroductionQ6
Theseguidelinesrepresentanoverviewofthebestpractice forEuropean
laboratories providing oral fluid workplace drug testing services to
maintain the legal defensibility of a drug test when the results, and the
medical interpretation of the results, are used in an employment disci-
plinary process, employment tribunal, or a court of law. These guidelines
are designed to ensure that the entire drug testing process is conducted
to give accurate and reliable information about a donor's drug use.
The updated oral fluid guidelines have been communicated within
the members of EWDTS and experts from different countries, and
accepted by the board.
In the age of globalisation, the legal basis for workplace drug and
alcohol testing has a complex structure consisting of international,
European, and national laws, acts, and regulations from different
levels.1 Since 1988, the European Workplace Drug Testing Society
(EWDTS) has offered a pan‐European platform to allow all sectors
involved in workplace drug testing (WDT) share best practices.
In 2010, the first guidelines were published as a handbook for
specimen collection, specimen analysis, and interpretation of the
results. Q7Since that time there have been goals and specific directives
which have impacted the WDT sector. This will continue with the
impact of further data protection and human rights legislation; for
example, GDPRs (General Data Protection Regulations). GDPR
EU‐2016/679 is a regulation Q8by which the European Parliament, the
Council of the European Union, and the European Commission intend
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to strengthen and unify data protection for all individuals within the
European Union (EU). In many European countries, there is no legal
mandate to test, and conversely there is no legislation to prevent a test
programme.
Most countries have implemented a testing regime in safety‐
critical workplace sectors, for example, nuclear, transportation, and
refinery operations. Testing programmes within the military and prison
systems are also prevalent in many countries.
Most European countries have no specific legislation on WDT. In
Belgium, Greece, Slovenia, Sweden, and Luxembourg further acts like
the Law on Safety and Health at the Workplace, Public Employment
Act, Code for Civil Servants, and others permit pre‐employment testing
or occupational physicians are authorised to make examinations when
required for specific jobs.
In the Czech Republic, Estonia, Ireland, Lithuania, and Slovakia,
WDT is regulated in the Labour Law or Safety, Health, and Welfare at
Work Acts or similar acts. In Italy, since 2007, WDT is established
and prescribed in the Decree on Health and Safety at Work (81/08) for
jobs which pose safety hazards to others.Q9 2 The Act on Workplace Drug
Testing permits WDT in Finland. By contrast, there is no legislation and
only alcohol testing can be done in Hungary: “The Act on Labour
Safety (No. 93/1993) does not authorise the labour safety controllers
to make drug tests.”Q10 In Austria, the Employee Protection Act defines
that the “employee is obliged not to be in a state caused by the use
of alcohol, medicines and drugs that endanger themselves or others.”
Q11 In Portugal and Germany, the responsibility for workers' safety and
health is part of the employers' duties. This “duty of care” requirement
is common in many countries, and in turn can be used to initiate a
testing protocol.Q12
Regarding the hierarchy of jurisprudence and all the different
national laws, it is necessary to set up additional recommendations
and to bring WDT procedures, which were already common in
practice, in line. Otherwise, companies and institutions may not be
able to implement the same procedure in all their offices, whether
or not the headquarters are based in Europe. EWDTS attempts to
ensure that WDT in Europe is performed to a defined quality
standard and in a legally secured way. The three main points of all
EWDTS guidelines are specimen collection, specimen analysis, and
interpretation of results. Some chapters handle general aspects like
“Laboratory Organisation” and “Quality Assurance and Quality
Control”, and these parts are identical in both the urine and oral fluid
guidelines.Q13
In the oral fluid guidelines, collection devices, collection
procedures, chain of custody, and validity testing are reported. As
there are different kits on the market – the focus is on oral fluid
collection devices, the components of the whole collection kit, and
the process of oral fluid collection. There should be a guarantee that
all oral fluid collection devices fulfil the requirement for exact determi-
nation of known volume. There is demand for precise determination of
the oral fluid amount in the collected sample to ensure accurate
calculation of drug concentrations. The use of “two sample containers,
demonstrably clean and unused” as well a “tamper‐evident seal for
each container” are further requests. In the subchapter “Oral Fluid
Collection Procedures”, the demand for A and B samples is described.
The measurement of endogenous biomarker in accordance with
reference values, an accurate known dilution factor, and sample vol-
ume are strongly recommended to verify the collected sample. Any
use of adulterants or efforts to tamper with samples by the donors
must be uncovered forcefully. In summary, the updated version of
the European Guidelines for Workplace Drug Testing in Oral Fluid
are geared towards bringing together different methods of operation
and ensuring best practice procedures.
2 | OBJECTIVES
• Provide a common framework for European providers of oral fluid
workplace drug testing services.
• Promote standards by providing guidelines which are accepted at a
European level.
• Ensure that the processes undertaken are capable of legal scrutiny.
• Provide safeguards to protect the dignity of the specimen donors
and the validity of the specimen.
• Define for laboratories common quality assurance and quality
control criteria that are capable of being accredited by an external
body.
• Ensure that the entire drug testing process is conducted to give
accurate and reliable information about drug use of the donor.
3 | SCOPE
These guidelines consider the three key stages of the workplace drug
testing process.
• Specimen collection: obtaining the oral fluid specimen from the
donor
• Laboratory analysis: analysing the sample for the presence of
drugs
• Interpretation: reviewing and interpreting the analytical results
4 | SERVICE PROVISION
Where a service provider is contracted to deliver all the stages, they
must ensure that the minimum criteria in this document are met in
all the key areas. In those instances where a customer may
undertake some stages of the process within their own organisation
(eg, specimen collection or interpretation), the service provider has a
‘duty of care’ to ensure that the customer understands the full
implications of the drug testing process. The service provider does
not have the authority to make decisions regarding the fitness for
work of any individual being tested. It is recommended that any
issues related to fitness for work be referred to the company's
medical representative.
5 | DRUG TESTING IN CONTEXT
It should be explained to any purchaser of a laboratory drug testing
service that drug testing should form part of an overall drug policy,
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which the purchaser has agreed with their employees and should have
in place before testing is initiated. The service provider should have an
effective company drugs policy in place. The policy may include drug
testing of the staff involved in the analysis and reporting of workplace
drug testing results.
6 | OUTLINE OF DRUG TESTING PROCESS
6.1 | Specimen collection
Oral fluid specimens for legally defensible drug testing need to be col-
lected under circumstances which respect the dignity of the individual
whilst ensuring that the specimen is freshly collected Suitable records
must be made when the specimen is collected to document that the
specimen collected and the specimen received by the laboratory are
one and the same. This is the first link in the chain of custody process
which, when reconstructed at a later date, can be used to document
that the final result belongs to the specimen collected.
6.2 | Analysis
When the specimen is received at the laboratory, checks on the integrity
of the specimen are carried out. Providing the specimen passes the
integrity checks, a portion of the specimen is taken and screened for
the presence of drugs and sample validity. If the screen results are all
negative, no further analysis is necessary. However, if the screen tests
carried out indicate the possible presence of a drug (above a predefined
cut‐off level), a confirmation test to prove or disprove the presence of
the drug or drug metabolite indicated by the screening test must be
carried out on another portion of the specimen.When a negative result
is obtained, either after the screen or the confirmation test, it can be
reported to the customer. Positive results may require interpretation.
6.3 | Interpretation
A laboratory positive result may be due to other reasons than intake of
illicit drugs (ie, prescribed, over‐the‐counter medication or dietary
causes). It requires interpretation that is best carried out by the
laboratory toxicologist in conjunction with a qualified medical
practitioner who can consult both with the donor and the donor's
medical practitioner.
6.4 | Record keeping
Suitable records must be made during the analytical process to docu-
ment that the specimen received by the laboratory and the specimen
about which the final report is written, are one and the same. All
samples which prove positive for the presence of drugs, and all records
of the analytical process, must be kept for an agreed period of time or
according to national legislation to allow for any challenges to be made
regarding the findings. If the customer requires an independent toxico-
logical review, the laboratory must make available, if requested, the
analytical data upon which it based its final report. The definitions
adopted for these guidelines are reported in TableT1 1.
7 | ORAL FLUID COLLECTION
7.1 | Introduction
This is the first link in the chain of custody process which, when
reconstructed at a later date, can be used to prove that the final result
belongs to the specimen collected. The collection process must be
carried out by someone formally assessed as competent and authorised
to carry out the collection. Standard Operating Procedures (SOPs) must
be written for the collection process, the storage of collection devices,
the training of Collecting Officers, and the shipping of the collected spec-
imen to the laboratory. These procedures must be followed precisely.
Collection procedures must cover the following aspects:
• Privacy and security of the specimen collection site.
• Steps to ensure that the specimen collection is supervised.
• Steps to protect against tampering and adulteration.
• Identification of the donor giving the specimen.
• Evidence of the written informed consent of the individual to the
analysis of the specimen (an example is given in Appendix B).
• Disclosure of recent medication, or evidence that the individual
was advised of the significance of recent medication.
• Confidentiality of all information received. Q14
All specimens for legally defensible drug testing must be collected
under circumstances that respect the dignity of the individual whilst
ensuring that the specimen is freshly generated and has not been tam-
pered with in any way. The collection site must be secure and the
absence of potential interfering substances must be guaranteed. The
validity of the specimen must be guaranteed.
Suitable records must be made when the specimen is collected to
prove that the specimen collected and the specimen received by the
laboratory are one and the same. Q15Where the customer takes responsi-
bility for the collection process, the service provider has a duty of care
to ensure that these guidelines are understood.
7.2 | Personnel
Specimens must be collected by suitably trained personnel (Collecting
Officers). Although no healthcare professional education is required,
documented training, which includes a demonstration of competence,
must be undertaken before collections are performed.
The training must include, at a minimum, instructions on the
following:
• Collection process.
• Storage and transport conditions of samples.
• Chain‐of‐custody process.
• Troubleshooting (ie, how to deal with issues like refusal of the test,
insufficient sample, suspicion of tampering of the sample, dry mouth)
• Responsibility of the Collecting Officer for maintaining donor
privacy, confidentiality of information, and specimen integrity.
• Ethical issues, especially regarding the declaration by the donor of
the present use of prescribed medications.
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On successful completion of collector training, a person may begin
performing collections.
7.3 | Oral fluid collection kits
The laboratory and the manufacturer must demonstrate that the
device in no way impairs the ability of the laboratory to detect the
drugs at the cut‐off levels recommended in these guidelines. It is
recommended that the device used to collect the oral fluid sample
collects a known volume. This may be achieved through spectrophoto-
metrical determination or through an integrated volume indicator. In
case of uncertainty, gravimetric analysis is strongly recommended.
Scientific data which demonstrate the accuracy of the volume of any
buffer (if used) and the collected sample must be available. The labora-
tory should be able to clearly identify which collection device has been
used to collect the sample.
TABLE 1 For purposes of these guidelines the following definitions have been adopted
Adulteration See Tampering
Aliquot A fractional part of a specimen used for testing. It is taken as a sample representing the whole specimen.
Authorising Scientist A person who reviews all pertinent data and quality control results in order to attest to the validity of the laboratory's test
reports.
Calibrator A solution of known concentration used to calibrate a measurement procedure or to compare the response obtained with
the response of a test sample/sample. The concentration of the analyte of interest in the calibrator is known within
limits ascertained during its preparation. Calibrators may be used to establish a calibration curve over a concentration
range of interest.
Chain of Custody Procedures to account for each specimen by tracking its handling and storage from point of collection to final disposal.
These procedures require that the donor identity is confirmed and that a chain of custody form is used from time of
collection to receipt by the laboratory. Within the laboratory appropriate chain of custody records must account for the
specimen until disposal.
Chain of Custody Form A form used to document the procedures from time of collection until receipt by the laboratory.
Collecting Officer A person trained to collect specimens from donors.
Collection Site A place where individuals present themselves to providing a specimen for analysis.
Confirmation Test An analytical procedure to identify and quantify the presence of a specific drug or metabolite which is independent of the
initial test and which uses a different aliquot technique and chemical principle from that of the screen test in order to
ensure reliability and accuracy.
Customer The organisation requesting the drug testing service.
Cut‐off A concentration level set to determine whether the sample is positive or negative for the presence of a drug.
Donor The individual from whom an oral fluid specimen is collected.
Derivative drugs/
metabolites
Drugs and metabolites that requires chemical modification for GC–MS analysis, ice, benzoylecgonine, temazepam
Laboratory The facility providing the analytical services to detect drugs of abuse.
Negative result A result reported by laboratory that indicates that either no drug is present in the sample or that any drug present is below
the cut‐off.
Observed Collection A donor gives the specimen under the direct observation of the collecting officer.
Positive result A result reported by the laboratory as positive means that there is conclusive evidence that a drug or drug metabolite is
present in the specimen tested at a level greater than or equal to the confirmation cut‐off concentration.
Quality control sample A sample used to evaluate if an analytical procedure is operating within pre‐defined tolerance limits.
Medical Review Officer
(MRO)
A medical physician responsible for receiving laboratory results from the drug‐testing laboratory who has knowledge of
substance abuse and has appropriate training or experience to interpret and evaluate an individual's positive test result,
in light of declared information.
Sample A representative portion of a specimen used by a laboratory for testing.
Screening Test A test to eliminate negative specimen from further consideration and to identify the presumptive positive specimen that
require confirmation testing.
Service Provider The organisation contracted to provide the drug testing service. This may be a laboratory, or a third party providing other
elements of the service, and sub‐contracting the tests to another laboratory.
Specimen The portion of oral fluid that is collected from a donor.
Standard (1) A reference material of known purity or a solution containing a reference material at a known concentration.
Standard (2) An agreed protocol or procedure (eg, EN ISO/IEC 17025 and EN ISO 15189)
Standard Operating
Procedure (SOP)
A written document giving the detailed steps to be followed when undertaking a particular task (eg, the analysis of a given
drug or drug metabolite in an oral fluid specimen).
Tampering Any process by which an individual knowingly interferes with (or attempts to interfere with) the processes of specimen
collection, transport, or analysis with the intention of avoiding a legitimate test result. The actions undertaken can
include (but are not limited to) the addition of water or foreign substances to the specimen, specimen substitution,
damaging bottle seals or packaging and the deliberate consumption of interfering substances or copious volumes of
water prior to specimen collection.
Toxicologist A person responsible for interpreting a toxicological analytical result for the customer or the customer's designated
Medical Review Officer.
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The collection kit should comprise the following components:
• Specimen collection device(s).
• Chain of custody donor form.
• A unique identifier that links the chain of custody form and sample
containers.
• At least two sample containers, demonstrably clean and unused.
• Tamper‐evident seal for each container.
• Packaging components that satisfy current postal and courier
regulations.
7.4 | Chain of custody forms
The minimum information required on the chain of custody form is:
• Unique identification to link the form to the specimen container(s)
(typically a barcode label or code number assigned to the sample).
• Information uniquely identifying the donor.
• Evidence that donor identity has been confirmed.
• Evidence that the donor has given informed consent for the
specimen to be tested.
• Date, time, and place of collection.
• Names and signatures of all individuals who had custody of the
specimen during the collection process.
• The opportunity to record any medication, prescribed or
non‐prescribed, that may have been taken in the days prior to
the specimen being collected.
• Copies for donor, employer, and laboratory.
7.5 | Oral fluid collection procedures
One sample is collected and then split in the presence of the donor
into two separate containers labelled Sample A and Sample B.
It is acknowledged that currently some oral fluid collection devices
cannot mechanically collect and generate two separate samples from
the single collection procedure. In this case, two devices may be used
to generate two samples. As these samples are discrete and not
homogeneous, the aliquots could be mixed and then divided into two
aliquots (A and B). The sequential collection should be done within
5 minutes of each other. In addition, the exact times of the generation
of the samples must be noted on the donor consent documentation.
The two samples are then sent to the testing facility. Regardless of
which type of device is used, there must be a “volume adequacy indi-
cator” on the device to show the collector that an adequate minimum
volume has been collected, if two separate collection procedures are
used to generate two samples. The receiving laboratory must
gravimetrically or spectrophotometrically determine a more precise
quantity of collected oral fluid present in the container. When
gravimetrical determination is used to measure collected oral fluid, it
is recommended to determine the average net weight of unused
collection devices for each batch. This known amount of oral fluid is
very important in the subsequent calculation of drug concentrations.
Individual manufacturer's tolerances must be known and confirmed.
In all cases, the testing laboratory should receive two samples, labelled
“A” and “B”. An example oral fluid collection protocol is detailed in
Appendix A.
8 | LABORATORY ORGANISATION
A Quality Management System of the organisation/laboratory is
required via accreditation according to EN ISO/IEC 17025 and/or EN
ISO 15189 in fields of forensic toxicology and/or WDT analysis.
All personnel must have contracts with the institution (Laboratory
Organisation) which they work for and every person must have agreed
to the “confidentiality policy” of the institution (in written form).
8.1 | Personnel
All personnel should adhere to the requirements of EN ISO/IEC 17025
and/or EN ISO 15189 International Standards and as such, only staff
who are suitably qualified and whose competence has been formally
assessed can work within the laboratory. The laboratory must maintain
accurate job descriptions for managerial, technical, and key support
personnel involved in the analytical tests.
The laboratory must keep records that establish the individual's
qualifications/competency for all functions performed. The individual's
file must include an up‐to‐date curriculum vitae listing educational
qualifications and previous employment experience, training, and
competency assessment records for the current tasks performed.
Personnel performing specific tasks shall be qualified based on
appropriate education, training, experience, and/or demonstrated
skills, as required. All laboratory personnel must have received training
in Health and Safety issues, the Control of Substances Hazardous to
Health (COSHH) Regulations, and other relevant legislation.
The key functions outlined in the following sections are identified
as the minimum requirement for a laboratory to maintain EN ISO
17025 and/or EN ISO 15189 accreditation for the provision of work-
place drug testing services and/or forensic toxicology. It is acceptable
for individuals to have responsibility to carry out more than one role.
By virtue of the laboratory's accreditation, it can be accepted that the
appropriate qualifications for each role are in place. Role titles may vary
between organisations, but the responsibilities will remain the same.
8.1.1 | Laboratory security
Drug testing laboratories must have a robust security system to ensure
that no unauthorised personnel gain access to the laboratory pro-
cesses or to areas where samples or records are stored, as
mentioned in EN ISO 17025 and/or EN ISO 15189. Unescorted access
to these secured areas must be limited to authorised individuals. The
laboratory must maintain a record that documents the entry and exit
of all visitors to the secured laboratory areas. The laboratory must
maintain a record of all staff who are authorised to enter the secure
laboratory areas. This list must be reviewed and updated on a regular
basis. Sample containers must be retained within the secure laboratory
area until the disposal date.
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8.1.2 | Laboratory director
There must be one person who has overall responsibility for the
professional, organisational, educational, and administrative activities
of the drug testing facility. This person is responsible for the day‐to‐
day management of the drug testing laboratory. Some of the functions
may be delegated to other appropriately qualified personnel but the
overall responsibility for any delegated functions will remain with the
designated laboratory director (typically the laboratory supervisor).
8.1.3 | Authorising scientist
A person responsible for the review and certification of pertinent data
and quality control results, prior to release of accurate and reliable
analytical results.
8.1.4 | Laboratory analyst
A person responsible for undertaking the day‐to‐day analytical
procedures.
8.1.5 | Toxicologist
A person responsible for interpreting a toxicological analytical result
for the customer or the customer's designated Medical Review Officer
(MRO).
8.1.6 | Expert witness
A person to present evidence to administrative or disciplinary proceed-
ings that are based on analytical results reported by the laboratory.
8.1.7 | Quality manager
A person responsible for quality assurance within the laboratory
organisation.
8.1.8 | Other personnel
Other technical or non‐technical staff who must have the necessary
training and skills for the tasks assigned.
9 | LABORATORY ANALYSIS PROCEDURES
9.1 | Process
When specimens are received at the laboratory, initial checks of the
sample's chain of custody and appearance are carried out. If the
specimen passes these checks, a portion of the specimen in container
A is taken and goes through initial screening tests for the presence
of drugs. Further testing of sample validity may also take place at this
point. If the screening results are all negative (below a pre‐defined
cut‐off level), no further analyses are necessary. However, if the
screening tests carried out indicate the possible presence of a drug
(above a pre‐defined cut‐off level), a confirmation test to prove or dis-
prove the presence of the drug or drug metabolite indicated by the
screening test must be carried out on another portion of the specimen.
The screen‐only presumptive positive test is not considered to be
legally defensible, but may report preliminary presumptive positive
results to the clients as local legislation allows. In the report, it must
be mentioned that preliminary presumptive positive results need
confirmation. If the first analysis is performed by a confirmation‐level
analysis (mass spectrometry), the positive findings must be retested
with another portion of the sample.
9.1.1 | Chain of custody
Laboratories must use chain of custody procedures to maintain
control and accountability of specimens and aliquots from receipt
through completion of testing, reporting of results, during storage,
and continuing until final disposal of specimens and aliquots. Chain
of custody records must be maintained on paper or in
computerised form.
9.1.2 | Sample receipt
The laboratory should receive at least two sealed sample containers
and a corresponding chain of custody form. At least one of these
(referred to in this document as container B) must be retained
unopened and stored in conditions that reflect the storage of the
sample under test (referred to in this document as container A).
When a sample is received in the laboratory:
• Incoming orders and samples must be registered by the laboratory.
• Incoming samples are immediately checked regarding complete-
ness, intactness, and suitability for testing.
• Its packaging must be examined for evidence of tampering in
transit.
• The information on the sample containers within the package must
be compared with the information on the accompanying chain of
custody form.
• Any discrepancies must be noted and, where appropriate, reported
immediately to the customer. Some minor discrepancies may be
tolerated in the documentation without termination of the
analysis. These must be agreed with the customer prior to analysis
and should be documented.
• Appendix C lists examples of fatal flaws in the chain of custody
and is provided for guidance. Flaws of this nature would normally
result in the sample not being tested.
9.1.3 | Sample processing
Separate representative portions (aliquots) of the sample in con-
tainer A will be used for screening and confirmation tests. The sam-
ple preparation should follow the SOP and the manufacturer's
instructions for the collection system being used. Aliquots must
be taken in such a manner that excludes the possibility of
contamination.
Short‐term storage
Samples that are not currently undergoing analysis must be
refrigerated at 2–8°C. Stability must be investigated and appropriate
measures undertaken to ensure the sample is valid for the analysis.
The long‐term storage conditions are device dependent and the
conditions should be as recommended by the device manufacturer.
The A and the B samples must be stored under identical conditions.
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The quality control requirements must be satisfied when conducting
either screening or confirmation tests, either on single samples or
samples grouped in batches.
9.2 | Oral fluid validity testing
The aim of validity testing is to demonstrate that the sample submitted
for analysis is oral fluid. The validity of the sample must be checked
either before or during the screening process. The minimum validity
test that must be completed for oral fluid is the visual inspection of
the sample(s), measurement of oral fluid volume and testing on matrix
authenticity through measurement of endogenous biomarkers (eg,
salivary amylase, cortisol …). The laboratory may also test for adulter-
ants and sample tampering.
The following data must be coherent:
• Collection time
• Dilution factor (gravimetrical analysis or measured
spectrophotometry)
• Sample volume
• Endogenous biomarker in accordance with reference values (eg,
salivary Amylase, Cortisol…)
9.2.1 | Testing for adulterants
Additional validity tests should be considered when the following
conditions are observed:
• Abnormal physical characteristics (eg, unusual colour or texture
for the specific used device through bleeding, unusual odour,
missing “pads” …)
• Reactions or responses characteristic of an adulterant obtained
during initial or confirmatory drug tests (eg, non‐recovery of
internal standards, unusual response); or possible unidentified
interfering substance or adulterant.
A sample should be reported as, for example, “Sample cannot be
used for screening and/or confirmation analysis” in the following
situations:
• A valid immunoassay drug test result cannot be obtained on two
separate aliquots (eg, a reasonable suspicion on interference
occurred).
• A valid drug test result cannot be obtained on two separate
aliquots with drug confirmatory assay (a reasonable suspicion on
interference occurred – eg, components in the buffer which might
interfere or cause ion suppression).
• The physical appearance of the sample is such that testing the
sample may damage the laboratory's instruments.
• Gravimetrical analysis exposes unexplainable deviation of weight
(ie, less weight caused by “sucked pads”, higher weight through
water in the mouth.)
• Spectrophotometrical analysis and measurement of endogenous
biomarker indicates a dilution of the sample with water.
10 | ANALYTICAL METHODS AND
VALIDATION
10.1 | Acceptable screening techniques
The following methods are accepted:
• Immunoassays
• Gas chromatography
• Liquid chromatography as ultra‐performance liquid chromatogra-
phy (UPLC)/ultra‐fast liquid chromatography (UFLC)
• All chromatographic techniques coupled to mass spectrometry
• Capillary zone electrophoresis
10.2 | Laboratory screening tests
The initial screening test must use an appropriate technique. The assay
using the selected technique must be validated prior to its use. Recom-
mended maximum screening calibration cut‐off concentrations for
workplace drug testing are listed in Table T22. These recommended
cut‐off concentrations may be subject to change reflecting advances
in technology and knowledge. Cut‐off concentrations for substances
not indicated in Table 2 will need to be agreed with the customer,
considering the performance of the assays to be used and the
pharmacokinetics of the drugs involved.
All screening test results must be reviewed regarding the results of
the validity tests performed.
Samples that test negative on all the initial screening tests and
pass the validity tests must be reported as negative and the samples
can be disposed of as agreed with the customer. Samples that test
negative on all the initial screening tests but fail the validity tests
may be further investigated to determine the reason.
The presumptive presence for any drug following the initial
preliminary screen must have the presence of the drug or drug
metabolite confirmed (Section 10.4). If the first analysis is performed
by a confirmation‐level analysis (mass spectrometry), the positive
findings must be confirmed and quantified by reanalysis with another
portion of the sample.
10.3 | Standardisation of laboratory screening assays
All assays must be calibrated against appropriate standards by follow-
ing laboratory protocols based on the manufacturer's recommenda-
tions or validated alternatives. The assay must be calibrated against
one named compound, and the cross‐reactivity to other related
compounds must be determined. The customer must be informed of
the limitations of the tests.
10.4 | Confirmation tests
The presence of the drugs indicated by a positive screening result must
be confirmed using a chromatographic technique in combination with
mass spectrometry (eg, gas chromatography–mass spectrometry
(GC‐–MS) or liquid chromatography–mass spectrometry (LC–MS)). If
the first analysis is performed by a confirmation‐level analysis (mass
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spectrometry), the positive findings must be confirmed and quantified
by reanalysis with another portion of the sample.
All confirmations must be quantitative. The customer must be
informed of the compounds detected in the confirmation tests. Rec-
ommended maximum confirmation cut‐off concentrations for work-
place drug testing are given in TableT3 3. The cut‐off concentrations
are a result of modern instrumentation techniques and the relatively
short detection time window in oral fluid matrices. These cut‐offs are
the maximum recommended cut‐offs for workplace drug testing
purposes. Confirmation cut‐off concentrations may be subject to
change as advances in technology or other considerations warrant
identification of substances at other concentrations.
Confirmation cut‐off concentration for substances not indicated in
Table 3 must be agreed with the customer, considering the perfor-
mance of the assays to be used and the pharmacokinetics of the drugs
involved. Samples that are below the agreed cut‐off concentration
must be reported negative. No further testing will be undertaken and
the samples may be discarded as per the customer agreed timetable.
Samples that contain drugs and/or metabolites at concentrations
greater than or equal to the agreed cut‐off level must be reported
positive. Laboratories must adhere to national and international
guidelines that specify additional criteria for chromatographic and
mass spectral acceptability.
11 | VALIDATION
All methods must be validated and their suitability for intended
purpose must be evaluated in accordance with EN ISO/IEC 17025.
TABLE 2 Recommended substances and maximum cut‐off concen-
trations for screening tests in oral fluid. Laboratory screen test cut‐off
concentration in neat oral fluid (ng/mL)
ng/mL
Amphetamines group 40
Cannabis (THC) 10
Cocaine + metabolites 30
Opiates (Morphine) 40
6‐AM 4
Methadone (l) 50
Benzodiazepines group 10
Buprenorphines 5
Propoxyphene or metabolites 40
Cut‐off under investigation / discussion:
Barbiturate ‐
Ketamine ‐
LSD or metabolites ‐
Other opioids (e.g. Oxycodone, Hydromorphone, Tramadol,
Buprenorphine, Tilidine, Fentanyl)
‐
Phencyclidine ‐
Pregabalin ‐
Synthetic cannabinoids (JWH‐018, JWH‐073) ‐
Synthetic cathinones (MDPV etc.) ‐
Z‐Drugs (Zopiclone, Zolpidem, Zaleplon) ‐
Note:
1Q20 The laboratory has to take into account country‐specific differences in the
drug‐panel they are using.
2These recommended cut‐off values may be subject to changes as advances in
technology or other considerations warrant identification of these substances
at other concentrations.
3Cut‐off levels for substances not indicated in Appendix D will need to be
agreed with the customer taking into account the performance of the assays
to be used. The toxicologist/laboratory must explain the meaning to the
customer.
4Dilution of the sample must be corrected for when the screen results are
interpreted.
5When using immunological analyses, the differences in cross‐reactivity of
different substances must be noted and factored into laboratory reports.
6The laboratory is responsible for remaining up to date with local drug trends
and has a responsibility to use this knowledge to advise the customer of the
most appropriate substances to be included in the drug testing panel.
TABLE 3 Recommended substances and maximum cut‐off concen-
trations for confirmation tests in oral fluid. Confirmation test cut‐off
concentration in neat oral fluid (ng/mL)
ng/mL
Amphetamine
Amphetamine (d + l) 15
Methamphetamine 15
MDA 15
MDMA 15
Other members of the amphetamine group
Benzodiazepine
7‐Amino‐flunitrazepam 3
7‐Amino‐clonazepam 3
7‐Amino‐nitrazepam 3
Alprazolam 3
Bromazepam 3
Clonazepam 3
Desmethyldiazepam 3
Diazepam 3
Flunitrazepam 3
Flurazepam 3
Lorazepam 3
Lormetazepam 3
Midazolam 3
Nitrazepam 3
Nordiazepam 3
Oxazepam 3
Phenazepam 3
Temazepam 10
Opiates
Morphine 15
Codeine 15
Norcodeine 2
Dihydrocodeine 15
6‐Monoacetylmorphine 2
Cannabis (THC) 2
Cocaine
Cocaine metabolite (Benzoylecgonine) 8
Cocaine 8
Cocaethylene ‐
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Laboratories accredited according to EN ISO 15189 should produce
evidence of adequate method validation and certificate of participation
to Proficiency Test and External Quality Assessment.
The following parameters must be determined at least for quanti-
tative confirmation analyses and whenever possible, for screening
analyses: precision, cut‐off verification, selectivity, limit of detection,
limit of quantification, sensitivity, specificity, stability, measurement
uncertainty, recovery of the collection device, and matrix effects.
12 | AUTHORISATION AND REPORTING OF
RESULTS
Before any laboratory test result is released, the results must be
reviewed and certified as accurate by a competent member of staff
(analytical validation). At a minimum, the report must include the
specimen identification number and the test result (positive/negative)
for each sample submitted. Reporting must be managed in accordance
with EN ISO/IEC 17025 and/or EN ISO 15189 requirements. In
addition, the cut‐off used for the test should be included. Only drugs
that have been confirmed by a recognised confirmation test can be
reported as positive. Samples that fail integrity or validity tests must
be identified to the customer on the report. The laboratory must define
and agree the meaning of all terms used in the report to the customer.
Results must be transmitted to the customer's designated representa-
tive in a manner that will ensure confidentiality of the information. Lab-
oratory results should not be provided verbally. Written or electronic
resultsmust be transmitted to the customer's designated representative
in a manner that will ensure confidentiality of the information.
13 | LONG‐TERM STORAGE OF SAMPLES
The laboratory must demonstrate that the long‐term storage condi-
tions of samples are adequate to ensure that analytes are stable over
the time period required for any re‐test. Currently long‐term deep‐fro-
zen storage (−20°C or below) indicates that most positive samples will
remain suitable for any necessary retest. Unless otherwise authorised
in writing by the customer, drug testing laboratories must retain all
samples confirmed positive in properly secured long‐term frozen
storage for a minimum of 1 year. Within this 1‐year period the
customer may request the laboratory to retain the sample for an
additional period of time. If no such request is received, the laboratory
may discard the sample after the end of 1 year. The laboratory shall be
required to maintain any samples known to be under legal challenge
for a further agreed period. Samples must be retained within the
secure laboratory area until the disposal date agreed with the
customer. Negative samples (A + B) samples may be discarded as per
the laboratory and customer agreed timetable.
14 | RECORDS
The laboratory must maintain and make available for an agreed period,
documentation of all aspects of the testing process involved in the
generation of a positive result.
The required documentation must include:
• Training and competency records for all individuals authorised to
have access to samples and sample data.
• Chain of custody forms.
• Quality assessment/quality control records.
• Standard operating procedures.
• All test data (including method validation, calibration curves and
calculations for determining test results).
• Maintenance and instrument calibration records.
• Reports.
• Records of proficiency testing and computer‐generated data.
The laboratorywill be required tomaintain documents for any sam-
ple under legal challenge for a further agreed period. Document control
must bemanaged in accordancewith EN ISO/IEC 17025 and/or EN ISO
15189 requirements and records containing details of individuals
should be dealt with in line with European Data Protection Legislation.
15 | QUALITY ASSURANCE AND QUALITY
CONTROL
15.1 | Quality assurance
Drug testing laboratories must have a quality management system
which encompasses all aspects of the testing process including but
not limited to:
• Sample receipt
• Chain of custody
• Security and reporting of results
• Screening and confirmation testing
• Certification of calibrators and controls
• Validation of analytical procedures
Quality assurance procedures shall be designed, implemented, and
reviewed to monitor the conduct of each step of the testing process.
The testing laboratory and all screening and confirmation tests used
in workplace drug testing must be fully validated and accredited by a
recognised external accreditation body. When an unaccredited
method is used the customer should be informed accordingly.
15.2 | Quality control
Calibrators and controls shall be prepared using either certified drug
referencematerials or certified standard solutions obtained, where pos-
sible, from two commercial manufacturers and should be appropriate to
the matrix. If two manufacturers are not feasible, then the controls
should be taken from separate lots from the same manufacturer.
The laboratory must retain records to demonstrate that all
calibrators and controls are traceable back to primary standards (if
available). The calibrators and controls shall be properly labelled as to
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content, concentration, data placed in service and expiry date. All
standards (eg, pure reference materials, stock standard solutions,
purchased standards) shall be labelled with the following:
• Date received (if applicable)
• Date prepared or opened or placed in service
• Expiration date
• Initials of the technicians who has prepared the (in house) calibra-
tor, etc
All data acquired on control samples as well as lot number of drug
reference materials must be recorded in such a way as to facilitate
interpretation of control results and trends.
16 | LABORATORY SCREENING TESTS
These are the minimum requirements for the suitable control of all
laboratory screening tests. A.
system suitability check must be carried out prior to the analysis of
samples. Screening tests are carried out using reagents and calibrators
directly provided by the manufacturers provided the analysis is carried
out according to the indications and the value of the cut‐off defined by
the manufacturer. Since the negative outcome of a screening analysis
is generally accepted as valid, it is essential to verify that the method
can minimise false negative results.
Assays must be calibrated weekly or when quality control samples
indicate poor performance. Control samples at concentrations of
approximately 50% below and above the cut‐off concentration for
each drug group must be included in every batch of samples. These
must be sourced independently from calibrators. Quality control
samples must comprise at least 5% of the total number of samples in
each batch being analysed.
17 | CONFIRMATION TESTS
These are the minimum requirements for identification of analytes and
confirmation of results.
17.1 | Identification
17.1.1 | Mass spectrometry coupled to chromatography
a. Mass spectrometry coupled to a chromatographic separation
method is a very powerful combination for identification of an
analyte in the sample extract. It simultaneously provides retention
time, ion/charge ratios and relative abundance (intensity) data.
Requirements for chromatography
a. The minimum acceptable retention time for the analytes under
examination should be at least twice the retention time
corresponding to the void volume of the column. The retention
time of the analytes in the extract should correspond to that of
the calibration standard (may need to be matrix‐matched) with a
tolerance of ±1%, for both gas chromatography and liquid
chromatography.
Tolerance 1% means (with rt: retention time):
rtanalyte in sample−rtanalyte in calibrator
rtanalyte in calibrator
≤0:01
Requirements for mass spectrometry (MS)
a. Reference spectra for the analytes should be generated using the
same instruments and techniques used for analysis of the samples.
If major differences are evident between a published spectrum
and the spectrum generated within the laboratory, the latter must
be shown to be valid.
b. Identification relies on proper selection of diagnostic (characteris-
tic) ions. The (quasi) molecular ion is a diagnostic ion that should
be included in the measurement and identification procedure
whenever possible. In general, and especially in single‐stage MS,
high m/z ions are more specific than low m/z ions (eg, m/z < 100).
c. Extracted ion chromatograms of sample extracts should have
peaks (exceeding S/N 3:1 of similar retention time, peak shape,
and response ratio to those obtained from a calibration standard
analysed at comparable concentration in the same batch. Shift in
retention time should not exceed 1% compared to calibration
standard. Chromatographic peaks from different selective ions
for the same analytes must overlap with each other. Where an
ion chromatogram shows evidence of significant chromatographic
interference, it must not be relied upon to quantify or identify res-
idues. The ion that shows the best signal‐to‐noise ratio and no
evidence of significant chromatographic interference should be
used for quantification.
d. In case of full‐scan measurement, careful subtraction of
background spectra, either manual or automatic, by
deconvolution or other algorithms, may be required to ensure
that the resultant spectrum of the chromatographic peak is rep-
resentative. Whenever background correction is used, this must
be applied uniformly throughout the batch and should be clearly
indicated.
e. Different types and modes of mass spectrometric detectors pro-
vide different degrees of selectivity and specificity, which relates
to the confidence in identification. General requirements for iden-
tification by MS methods have been published and should be
regarded as guidance criteria for identification, not as absolute
criteria to prove presence or absence of a compound.
f. The relative intensities or ratios of selective ions (full‐scan MS or
SIM) or product ions (MS/MS), expressed as a ratio relative to the
most intense (product) ion, should correspond to those of the
calibration standard at comparable concentrations and measured
under the same conditions. Matrix‐matched calibration solutions
may need to be used. Table T44 indicates the maximum tolerances
for ion ratios.3
g. The variability of ion ratios should preferably be determined from
calibration standards during initial method validation and
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subsequently during routine analysis. Diagnostic ions should have
an ion ratio of >0.05 (least/most intense ion).
h. At higher deviationof the relative abundanceof a qualifier ion, anal-
ysis needs to be repeated. If tolerances remain beyond acceptance
criteria, further investigation of influences of matrix effects or
disturbing compound are recommended – such as standard addi-
tion experiments or chance of chromatographic system – to verify
or to exclude the presence of a compound. In these cases, comple-
mentary interpretation by an experienced analyst is recommended.
i. For more confidence in identification, further evidence may be
achieved from additional mass spectrometric information. For
example, evaluation of full‐scan spectra, isotope pattern, adduct
ions, additional accurate mass fragment ions, additional product
ions (inMS/MS), or accuratemass product ions. For high resolution
mass spectrometry (HRMS) the mass resolution shall typically be
greater than 10 000 for the entire mass range at 10% valley (which
equates to resolving power of 20 000 FWHM (full width at half
maximum). For accurate mass measurements (AMM) the instru-
ment mass error in routine mass measurements must be less than
2 mDa and resolution shall typically be greater than 5000 FWHM.
For combination of LC with high‐resolution quadrupole time‐of‐
flight tandem mass spectrometry (HR–QToF–MS/MS) or other mass
spectrometric technique with HR–MS/MS the following settings are
recommended for mass spectral identification based on a mass spectral
library (commercial or home‐made):
For HR‐QToF‐MS/MS analysis, a mass resolution of >10 000 amu
with a mass accuracy of <5 ppm and an isotope ratio comparability of
better than 80% should be used in routine analysis. If comparison to a
library is performed with MS/MS spectra, a fit value of >70% should be
used as a threshold, for identification of compounds. Additionally, 1%
tolerance of LC‐retention time is required (Point e).
a. The chromatographic profile of the isomers of an analyte or any
relevant metabolites may also provide evidence. Additional evi-
dence may be sought using a different chromatographic
separation system and/or a different MS‐ionisation technique.
18 | CONFIRMATION OF RESULTS.
If the initial analysis does not provide unambiguous identification or
does not meet the requirements for quantitative analysis, a confirma-
tory analysis of sample A is required. This may involve reanalysis of
the extract or the sample. In cases where a detection threshold for a
drug is exceeded, a confirmatory analysis of a portion of sample B
may be required by the authorities. For unusual analyte/matrix combi-
nations, a confirmatory analysis is also recommended.
The use of different determination techniques and/or confirma-
tion of qualitative and/or quantitative results by an independent
expert laboratory will provide further supporting evidence.
18.1 | External quality assessment
The laboratory must take part in appropriate external quality assess-
ment schemes. When the scheme is not available, the laboratory must
conduct appropriate inter‐laboratory testing to ensure appropriate
assay performance.
18.2 | Sub‐contracting
Drug testing laboratories should carry out all laboratory work with
their own personnel and equipment. If it is necessary to sub‐contract,
inter‐laboratory transfer of samples is performed with strict adher-
ence to chain of custody procedures. The sub‐contracted laboratory
and its methods must be accredited by a recognised external
accrediting body and compliant with these guidelines. Analyses
undertaken by sub‐contracted laboratories must be identified on
the test report to the customer.
18.3 | Interpretation of results
A confirmed analytical positive result may be due to medication
(prescribed or over‐the‐counter) or due to dietary causes. An
essential part of the drug testing process is the final review of
analytical results. The interpretation is best carried out by a qualified
medical professional (eg, MRO) or a Forensic Toxicologist (depending
on the country‐specific situation).
18.4 | Toxicology review
It is mandatory that a toxicologist is available to advise the customer
and/or MRO regarding queries with test results.
18.5 | Medical review
The MRO is a medical physician with responsibility for interpreting
laboratory results together with a toxicologist. Depending on the
country‐specific situation a medical physician usually has greater
access to medical records than a toxicologist and may therefore be in
a better position to provide interpretation of positive analytical results.
The MRO must have specialist knowledge of and training in
• specimen collection procedures,
• analytical procedures,
• chain of custody, and
• alternative explanations for positive analytical results.
The MRO can issue a negative report for a positive analytical
result if the test result is likely to be due to the use of declared
TABLE 4 Recommended maximum tolerances for ion ratios using
different MS techniques
Ion ratio
(least/most
intense ion)
Maximum tolerance
(relative) for GC–EI–
MS
Maximum tolerance (relative)
for GC–CI–MS, GC–MSn, LC–
MS, LC–MSn**
>50% 20% 20%
>20%–50% 20% 25%
>10%–20% 25% 30%
≤10% 50% 50%
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medication, or a valid alternative medical explanation has been
found.
The service provider may provide access to an independent
medical review service.
18.6 | Challenges to drug test results
In situations where there is a challenge to the results of a positive drug
test result, the following guidelines must be used. Sample” should be
released for analysis to a drug testing laboratory accredited by a
recognised external accrediting body and working to these guidelines.
This release requires authorisation from both the customer/MRO and
the donor.
The release must be supported by chain of custody procedures
that can withstand legal scrutiny and include information about the
findings of the original test (corresponding sample A) and the cut‐offs
used for the test. The original laboratory must retain the residue of
the original sample and its containers so that it can be compared with
sample B later if required.
All laboratories that undertake B‐sample testing must be able
to demonstrate that they can accurately determine the concentra-
tion of a drug or metabolite at 50% of the recommended confirma-
tion cut‐off concentration listed in Appendix E (or the cut‐off used
for the original test, whichever is the lower). On receipt in the
testing laboratory, the B sample should follow chain of custody
procedures as outlined. It is recommended that the laboratory
should carry out validity checks outlined prior to carrying out the
confirmation analysis. Only those drugs identified for confirmation
testing should be looked for. The final report on the B sample must
say either that there was no drug found, or a named drug was
found at a level that is either consistent or inconsistent with the
level in the corresponding sample A. Confirmation cut‐off levels
are not to be used as the determinant. There must be no comment
on the final report that states whether the sample is positive or
negative.
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APPENDIX A
Oral fluid collection procedure
(Note: Only formally competence tested and authorised persons may act
as Collecting Officers. Medical qualification is NOT required for Collecting
Officers.)
I. Collection site
Procedures shall provide for a designated collection site to be
secure. During the collection process, the collection site must be ded-
icated solely to sample collection and comply with all local health and
safety requirements.
II. Access to authorised personnel only
Only authorised personnel shall be permitted in any part of the
designated collection site when oral fluid samples are being collected
or stored.
III. Chain of custody
During the collection process chain of custody forms will be com-
pleted fully by the Collecting Officer and donor.
IV. Identification of the donor
When a donor arrives at the collection site, the Collecting
Officer will request that the donor presents photographic
identification. If the donor does not have acceptable photographic
identification, the Collecting Officer will obtain a positive
identification of the donor by an authorised supervisor or man-
ager within the parent organisation. If the donor's identity cannot
be established, the Collecting Officer will not proceed with the
collection.
V. Informing the donor about the test
The donor must be informed about the purpose and the content of
the test.
VI. Consent of the donor
The donor gives their consent for oral fluid collection and analysis
of drugs by signature. If the donor refuses to give a sample, a note to
this effect should be recorded on the form designated for that pur-
pose. Appendix 2 gives an example of a Donor's Statement of
Informed Consent.
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VII. Privacy
Procedures for collecting oral fluid specimens shall allow, where
possible, for donor privacy during sample collection. Donors must be
treated equally regardless of gender and any physical impairment.
The process should avoid embarrassment but should also be rugged
enough to satisfy challenge of the sample integrity. If there is a strong
suspicion of sample adulteration and/or the previous sample was adul-
terated, the sample can be collected under the supervision of the
Collecting Officer.
VIII. Integrity of the specimen
The Collecting Officer must adopt procedures to minimise the risk
of tampering and adulteration of the specimen during collection. The
following minimum precautions shall be taken to ensure that unadul-
terated specimens are obtained and correctly identified:
a. Throughout the collection process, the Collecting Officer will
note any unusual behaviour of the donor on the chain of custody
form.
b. The Collecting Officer will ask the donor to remove any articles
from the mouth, for example chewing gum.
c. The Collecting Officer will wait for 10 minutes to observe that
the donor has nothing in their mouth.
d. Oral fluid samples will then be collected from the donor and pre-
pared for analysis in strict accordance with the standard operat-
ing procedure and the manufacturer's instructions for the
collection system being used.
e. Upon receiving the specimen from the donor, the Collecting Offi-
cer will:
• Note collection time.
• Check the volume of oral fluid on/in the specimen collection
device.
• Inspect the specimen to determine its colour and appearance
of any signs of contaminants and adulteration.
f. Any unusual findings will be noted on the chain of custody form.
g. If the volume is less than that required by recommendation/order
of the laboratory, the specimen will be discarded and a second
specimen will be collected.
h. If the donor is unable to provide a suitable volume of oral fluid for
analysis, the collection process is stopped and advice should be
sought.
i. Both the donor and the Collecting Officer will keep the specimen
container(s) in view at all times prior to the oral fluid specimen(s)
being sealed and labelled.
j. The Collecting Officer will request the donor to observe the
transfer of the specimen to two sample containers and the
attachment of the tamper‐evident seal to the containers. The
same is requested if split samples are obtained by two devices.
The tamper‐evident seal ensures that any tampering with the
specimen will be evident to laboratory personnel during the labo-
ratory receipt.
k. The specimen container(s) will have an identification label that
contains at a minimum; the date, the donor's specimen number
and the donor's signature/initials. The Collecting Officer will
enter all information on the chain of custody form to identify
the origin of the specimen. Both specimen containers and all
pages of the chain of custody will be labelled at the time of collec-
tion with a unique identifier.
l. The Collecting Officer will explain the significance relating to
the drugs and medicines consumed within a minimum of
7 days prior to the provision of the oral fluid specimen.
The donor will be given the opportunity to declare any
medication used.
m. The donor will be asked to read and sign a statement on the
chain of custody form certifying that the specimen identified
on the form was in fact the specimen provided by the donor
and giving informed consent for the work to be undertaken.
Appendix 2 gives an example of a Donor's Statement of
Informed Consent.
n. The Collecting Officer will complete the specimen chain of cus-
tody form and package with the oral fluid specimen ready for dis-
patch together to the analytical laboratory. If the specimen is not
dispatched at once, during storage prior to dispatch the
Collecting Officer must give appropriate consideration to the
temperature and security of the specimens. It is advised that
the specimens should be refrigerated whenever possible (do not
freeze).
o. Other pages of the chain of custody form will be given or
forwarded to the appropriate persons.
p. The Collecting Officer and the donor will be present throughout
the procedures outlined in the paragraphs of this section.
IX. Exceptional situations
a. The donor wants to give the sample later
The Collecting Officer must not allow the donor to leave the
collection site and come back later to give a sample. The
Collecting Officer will contact the appropriate authority to obtain
guidance on the action to be taken.
b. Admission of illegal drug use
If the donor admits illegal drug use, this should be noted on the
chain of custody form.
X. Transportation to laboratory
Collecting Officers will arrange to dispatch the collected
specimens to the drug‐testing laboratory. The specimens will be placed
in containers designed to minimise the possibility of damage during
shipment and packed properly to comply with local/international mail
and courier regulations for biological specimens. Since specimens and
the corresponding documents are sealed in packages that would
indicate any tampering during transit to the laboratory by couriers,
carriers, and postal services, usually there is no requirement for
documented chain of custody procedures for the transport of the
package.
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APPENDIX B
Example of a Donor's Statement of Informed ConsentI
confirm that I have received information about the meaning
and content of the drug test. I confirm that I have provided a
sample of my oral fluid to the specimen collector. I have
observed the specimen being placed and sealed in the
specimen containers and I confirm that the information on
this form and on the specimen labels is correct. I hereby give
permission for a minimum of two sealed specimen containers
to be sent to the laboratory and I consent that they be tested
for evidence of drug use and for tests to be carried out to
confirm the validity of the sample. Furthermore, I understand
that the results will be communicated confidentially to the
employer or a designated representative.
I consent to the above.
Donor's name (block capitals):_____________________________
Donor's signature:_____________________________
Date:_____________________________
Donor's identifier on the specimen labels.
(if different from above):_____________________________
APPENDIX C
Some examples of fatal flaws in the chain of custody
1. A unique identifier (eg, barcode) is mismatched or absent.
2. No documentation received with the sample.
3. No written consent to test from the donor.
4. Seals broken or tampered with on the sample container/transport
container.
5. No seals.
6. Only 1 sample received.
7. Insufficient sample for complete analysis.
8. Leaking sample.
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